The first antisense nucleic acid drug in China has been approved for clinical research

Source: on April 19, 2018, the Ministry of science and technology approved the first antisense nucleic acid drug "ct102 for injection" to enter the clinical trial China is a country with high incidence of liver cancer, and the treatment of liver cancer is very limited Ct102 for injection is expected to provide a new gene targeted treatment for liver cancer patients It is understood that researcher Wang Shengqi of the Academy of military medicine presided over the research and development of "ct102 for injection" His team has been devoted to the research of antisense nucleic acid drugs since 1990 in China With the support of NSFC, National 863 program and national major new drug creation project, he has conquered the clinical design, large-scale preparation and quality control of such drugs The bottleneck of key technologies in pre-R & D In 2009, they cooperated with Hangzhou Tianlong Pharmaceutical Co., Ltd to develop anti-tumor and anti viral antisense nucleic acid drugs such as ct102 In 2012, with the approval of national development and Reform Commission and Zhejiang Province, the two sides established the first national and local joint Engineering Research Center for nucleic acid drugs in China According to the team experts, antisense nucleic acid drugs are a kind of gene targeted therapy drugs with high inhibition efficiency and good specificity, which can be used for the treatment of various types of tumors, viral infectious diseases, metabolic diseases and vascular diseases Because of its clear target, easy design and Realization of the treatment of diseases from the "source", it is considered to be a very promising drug High selectivity and high efficiency of potential therapeutic drugs So far, four antisense nucleic acids have been approved for marketing in foreign countries Ct102 is an antisense nucleic acid drug targeting IGF1R gene, which has independent intellectual property rights in China